{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:37:28Z","timestamp":1791398248300,"version":"4.3.3"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T00:00:00Z","timestamp":1433289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite affecting approximately one-quarter of all patients undergoing axillary lymph node dissection, the pathophysiology of breast cancer-related lymphoedema (BCRL) remains poorly understood. More extensive locoregional treatment and higher body mass index have long been identified as major risk factors. This study aimed to identify risk factors for BCRL with a specific focus on the potential impact of chemotherapy on the risk of BCRL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective analysis of a cohort of consecutive patients with breast cancer treated at a major London regional teaching hospital between 1 January 2010 and 31 December 2012. All patients had node-positive disease and underwent axillary lymph node dissection. Data regarding tumour-, patient- and treatment-related characteristics were collected prospectively. The diagnosis of BCRL was based on both subjective and objective criteria. Multivariable Cox proportional hazards regression was used to assess the association between treatment and risk of BCRL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Some 27\u00b71 per cent of all patients (74 of 273) developed BCRL over the study period. Administration of taxanes showed a strong association with the development of BCRL, as 52 (33\u00b75 per cent) of 155 patients who received taxanes developed BCRL. Multivariable Cox regression analysis demonstrated that patients who received taxanes were nearly three times more likely to develop BCRL than patients who had no chemotherapy (hazard ratio 2\u00b782, 95 per cent c.i. 1\u00b731 to 6\u00b706). No such increase was observed when taxanes were administered in the neoadjuvant setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present findings suggest that adjuvant taxanes play a key role in the development of BCRL after surgery. This may support the use of taxanes in a neoadjuvant rather than adjuvant setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bjs.9846","type":"journal-article","created":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T23:01:31Z","timestamp":1433372491000},"page":"1071-1078","source":"Crossref","is-referenced-by-count":62,"title":["Adjuvant taxanes and the development of breast cancer-related arm lymphoedema"],"prefix":"10.1093","volume":"102","author":[{"given":"M","family":"Cariati","sequence":"first","affiliation":[{"name":"Section of Research Oncology, King's College London, London, UK"},{"name":"Guy's and St Thomas' NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S K","family":"Bains","sequence":"additional","affiliation":[{"name":"Section of Research Oncology, King's College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Grootendorst","sequence":"additional","affiliation":[{"name":"Section of Research Oncology, King's College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Suyoi","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Mortimer","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, St George's, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Ellis","sequence":"additional","affiliation":[{"name":"Section of Research Oncology, King's College London, London, UK"},{"name":"Guy's and St Thomas' NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Harries","sequence":"additional","affiliation":[{"name":"Section of Research Oncology, King's College London, London, UK"},{"name":"Guy's and St Thomas' NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Van Hemelrijck","sequence":"additional","affiliation":[{"name":"School of Medicine, Cancer Epidemiology Group, Division of Cancer Studies, King's College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A D","family":"Purushotham","sequence":"additional","affiliation":[{"name":"Section of Research Oncology, King's College London, London, UK"},{"name":"Guy's and St Thomas' NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,6,3]]},"reference":[{"key":"2021022218481579300_bjs9846-bib-0001","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jemt.1163","article-title":"Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology","volume":"55","author":"Witte","year":"2001","journal-title":"Microsc Res Tech"},{"key":"2021022218481579300_bjs9846-bib-0002","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1053-4296(03)00038-9","article-title":"The grading of lymphedema in oncology clinical trials","volume":"13","author":"Cheville","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"2021022218481579300_bjs9846-bib-0003","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archsurg.138.5.482","article-title":"Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer","volume":"138","author":"Blanchard","year":"2003","journal-title":"Arch Surg"},{"key":"2021022218481579300_bjs9846-bib-0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jso.20373","article-title":"The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance","volume":"92","author":"Leidenius","year":"2005","journal-title":"J Surg Oncol"},{"key":"2021022218481579300_bjs9846-bib-0005","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/bjs.9401","article-title":"Arm lymphoedema after axillary surgery in women with invasive breast cancer","volume":"101","author":"Sackey","year":"2014","journal-title":"Br J Surg"},{"key":"2021022218481579300_bjs9846-bib-0006","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/qjmed\/89.5.377","article-title":"The prevalence of arm oedema following treatment for breast cancer","volume":"89","author":"Mortimer","year":"1996","journal-title":"QJM"},{"key":"2021022218481579300_bjs9846-bib-0007","first-page":"2235","article-title":"Lymphoedema of the arm after primary treatment of breast cancer","volume":"18","author":"Sch\u00fcnemann","year":"1998","journal-title":"Anticancer Res"},{"key":"2021022218481579300_bjs9846-bib-0008","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","article-title":"Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis","volume":"14","author":"DiSipio","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021022218481579300_bjs9846-bib-0009","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12B+<2814::AID-CNCR31>3.0.CO;2-E","article-title":"Precipitating factors in lymphedema: myths and realities","volume":"83","author":"Rockson","year":"1998","journal-title":"Cancer"},{"key":"2021022218481579300_bjs9846-bib-0010","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ijrobp.2010.01.001","article-title":"Standardized method for quantification of developing lymphedema in patients treated for breast cancer","volume":"79","author":"Ancukiewicz","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021022218481579300_bjs9846-bib-0011","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/lrb.2005.3.208","article-title":"A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population","volume":"3","author":"Armer","year":"2005","journal-title":"Lymphatic Res Biol"},{"key":"2021022218481579300_bjs9846-bib-0012","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/026921559701100301","article-title":"A review of outcome indicators in the treatment of chronic limb oedema","volume":"11","author":"Sitzia","year":"1997","journal-title":"Clin Rehabil"},{"key":"2021022218481579300_bjs9846-bib-0013","first-page":"122","article-title":"Non-invasive assessment of the lymphedematous limb","volume":"33","author":"Stanton","year":"2000","journal-title":"Lymphology"},{"key":"2021022218481579300_bjs9846-bib-0014","first-page":"77","article-title":"Validation of an optoelectronic limb volumeter (Perometer)","volume":"30","author":"Stanton","year":"1997","journal-title":"Lymphology"},{"key":"2021022218481579300_bjs9846-bib-0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ejso.2014.12.006","article-title":"Self perceived, but not objective lymphoedema is associated with decreased long-term health-related quality of life after breast cancer surgery","volume":"41","author":"Sackey","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"2021022218481579300_bjs9846-bib-0016","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1046\/j.1365-2168.2000.01569.x","article-title":"Lymphoedema following surgery for breast cancer","volume":"87","author":"Pain","year":"2000","journal-title":"Br J Surg"},{"key":"2021022218481579300_bjs9846-bib-0017","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ctrv.2007.11.002","article-title":"Breast cancer-related lymphoedema risk reduction advice: a challenge for health professionals","volume":"34","author":"Nielsen","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"2021022218481579300_bjs9846-bib-0018","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/028418600750013113","article-title":"Morbidity related to axillary irradiation in the treatment of breast cancer","volume":"39","author":"Bentzen","year":"2000","journal-title":"Acta Oncol"},{"key":"2021022218481579300_bjs9846-bib-0019","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12B+<2788::AID-CNCR27>3.0.CO;2-I","article-title":"Breast radiotherapy and lymphedema","volume":"83","author":"Meek","year":"1998","journal-title":"Cancer"},{"key":"2021022218481579300_bjs9846-bib-0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.clon.2005.11.004","article-title":"Complications of breast-cancer radiotherapy","volume":"18","author":"Senkus-Konefka","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2021022218481579300_bjs9846-bib-0021","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/archsurg.2010.231","article-title":"Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study","volume":"145","author":"Kwan","year":"2010","journal-title":"Arch Surg"},{"key":"2021022218481579300_bjs9846-bib-0022","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1089\/lrb.2012.0011","article-title":"Normative volume difference between the dominant and nondominant upper limbs in healthy older women","volume":"10","author":"Dylke","year":"2012","journal-title":"Lymphat Res Biol"},{"key":"2021022218481579300_bjs9846-bib-0023","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10549-010-1167-6","article-title":"A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance","volume":"125","author":"Wernicke","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2021022218481579300_bjs9846-bib-0024","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2008.16.3725","article-title":"Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements","volume":"26","author":"McLaughlin","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021022218481579300_bjs9846-bib-0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1245\/ASO.2006.05.013","article-title":"Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial","volume":"13","author":"Wilke","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"2021022218481579300_bjs9846-bib-0026","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djj158","article-title":"Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial","volume":"98","author":"Mansel","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2021022218481579300_bjs9846-bib-0027","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/01.sla.0000245472.47748.ec","article-title":"Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients","volume":"245","author":"Langer","year":"2007","journal-title":"Ann Surg"},{"key":"2021022218481579300_bjs9846-bib-0028","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/bjs.9766","article-title":"Global abnormalities in lymphatic function following systemic therapy in patients with breast cancer","volume":"102","author":"Bains","year":"2015","journal-title":"Br J Surg"},{"key":"2021022218481579300_bjs9846-bib-0029","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1055-9965.EPI-09-1245","article-title":"Risk factors for lymphedema after breast cancer treatment","volume":"19","author":"Norman","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021022218481579300_bjs9846-bib-0030","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1517\/14656566.9.15.2603","article-title":"Paclitaxel and docetaxel in the treatment of breast cancer","volume":"9","author":"Saloustros","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"2021022218481579300_bjs9846-bib-0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026946","article-title":"Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30 698 patients","volume":"6","author":"Qin","year":"2011","journal-title":"PLoS One"},{"key":"2021022218481579300_bjs9846-bib-0032","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004421.pub2","article-title":"Taxanes for adjuvant treatment of early breast cancer","author":"Ferguson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2021022218481579300_bjs9846-bib-0033","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0140-6736(11)61823-0","article-title":"The 2011 EBCTCG polychemotherapy overview","volume":"379","author":"Palmieri","year":"2012","journal-title":"Lancet"},{"key":"2021022218481579300_bjs9846-bib-0034","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","article-title":"Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021022218481579300_bjs9846-bib-0035","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(94)90754-4","article-title":"The taxoids: paclitaxel and docetaxel","volume":"344","author":"Gelmon","year":"1994","journal-title":"Lancet"},{"key":"2021022218481579300_bjs9846-bib-0036","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.1998.16.10.3426","article-title":"Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment","volume":"16","author":"Semb","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021022218481579300_bjs9846-bib-0037","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2125.1997.00613.x","article-title":"The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication","volume":"43","author":"B\u00e9har","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"2021022218481579300_bjs9846-bib-0038","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1089\/lrb.2014.0030","article-title":"Lymphedema following taxane-based chemotherapy in women with early breast cancer","volume":"12","author":"Lee","year":"2014","journal-title":"Lymphat Res Biol"},{"key":"2021022218481579300_bjs9846-bib-0039","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1055\/s-2007-1006411","article-title":"Lymphatic regeneration following microvascular limb replantation: a qualitative and quantitative animal study","volume":"13","author":"Anthony","year":"1997","journal-title":"J Reconstr Microsurg"},{"key":"2021022218481579300_bjs9846-bib-0040","doi-asserted-by":"crossref","first-page":"804675","DOI":"10.1155\/2013\/804675","article-title":"Lymphedema and therapeutic lymphangiogenesis","volume":"2013","author":"Saito","year":"2013","journal-title":"Biomed Res Int"},{"key":"2021022218481579300_bjs9846-bib-0041","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1152\/physrev.00005.2002","article-title":"Vascular growth factors and lymphangiogenesis","volume":"82","author":"Jussila","year":"2002","journal-title":"Physiol Rev"},{"key":"2021022218481579300_bjs9846-bib-0042","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni1013","article-title":"Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins","volume":"5","author":"Karkkainen","year":"2004","journal-title":"Nat Immunol"},{"key":"2021022218481579300_bjs9846-bib-0043","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1172\/JCI15830","article-title":"VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema","volume":"111","author":"Yoon","year":"2003","journal-title":"J Clin Invest"},{"key":"2021022218481579300_bjs9846-bib-0044","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0463.2004.apm1120306.x","article-title":"Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study","volume":"112","author":"Lennern\u00e4s","year":"2004","journal-title":"APMIS"},{"key":"2021022218481579300_bjs9846-bib-0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/07357900902744510","article-title":"Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice","volume":"28","author":"Jiang","year":"2010","journal-title":"Cancer Invest"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.9846","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/102\/9\/1071\/36336963\/bjs9846.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/102\/9\/1071\/36336963\/bjs9846.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T10:13:28Z","timestamp":1621505608000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/102\/9\/1071-1078\/6136668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,3]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,6,3]]},"published-print":{"date-parts":[[2015,7,14]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.9846","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,8]]},"published":{"date-parts":[[2015,6,3]]}}}